

Freedom of Information Request: Our Reference CTMUHB_435_21

You asked:

Q1. How many patients were treated in September 2021 (or latest available month) by dermatology with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olmiant)
- Bimekizumab (Bimzelx)
- Brodalumab (Kyntheum)
- Dupilumab (Dupixent)
- Ixekizumab (Taltz)
- Risankizumab (Skyrizi)
- Guselkumab (Tremfya)
- Secukinumab (Cosentyx)
- Tildrakizumab (Ilumetri)
- Tralokinumab (Adtralza)
- Ustekinumab (Stelara)

Q2. How many patients were treated in September 2021 (or latest available month) by rheumatology with the following drugs:

- Baricitinib (Olmiant)
- Filgotinib (Jyseleca)
- Guselkumab (Tremfya)
- Ixekizumab (Taltz)
- Secukinumab (Cosentyx)
- Tofacitinib (Xeljanz)
- Upadacitinib (Rinvoq)
- Ustekinumab (Stelara)

Our response:

Please see provided below, tables populated with data captured on our Medicines Management system for Q1 & Q2. The period relates to the month of September 21.

Please note, our patient numbers appear low, as the majority of patients requiring treatment with the medicines outlined in your request would be referred into the services of a neighbouring Health Board. For Merthyr & Cynon and Rhondda, Taff Ely Localities patients are referred to Cardiff and the Vale University Health Board and for Bridgend Localities patients treatments are serviced by Swansea Bay University Health Board.

Q1 - Dermatology	No Of Patients
Abrocitinib (Cibinqo)	0
Baricitinib (Olmiant)	**
Bimekizumab (Bimzelx)	0
Brodalumab (Kyntheum)	0
Dupilumab (Dupixent)	20

Q2 - Rheumatology	No Of Patients
Baricitinib (Olmiant)	**
Filgotinib (Jyseleca)	0
Guselkumab (Tremfya)	0
Ixekizumab (Taltz)	**
Secukinumab (Cosentyx)	38

Ixekizumab (Taltz)	0	Tofacitinib (Xeljanz)	9
Risankizumab (Skyrizi)	0	Upadacitinib (Rinvoq)	**
Guselkumab (Tremfya)	0	Ustekinumab (Stelara)	6
Secukinumab (Cosentyx)	0		
Tildrakizumab (Ilumetri)	0		
Tralokinumab (Adtralza)	0		
Ustekinumab (Stelara)	0		

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.